CJC-1295
CJC-1295 (without DAC)
A synthetic analogue of growth hormone-releasing hormone (GHRH). The 'without DAC' version provides a shorter, more physiological GH pulse compared to the DAC version.
Quick Reference
Mechanism of Action
CJC-1295 (no DAC) binds to GHRH receptors in the pituitary gland, stimulating the release of growth hormone in a pulsatile pattern that mimics natural GH secretion. When combined with a GHRP like Ipamorelin, it produces a synergistic amplification of GH release.
Health Claims & Evidence
Stimulates pulsatile growth hormone release
Improves body composition and reduces adiposity
Enhances recovery and muscle protein synthesis
Improves sleep quality
Short-Term Effects
Improved sleep quality, increased energy, mild water retention initially. GH pulse elevation within 30 minutes of injection.
Long-Term Effects
Progressive improvements in body composition, recovery, and skin quality over 8–12 week cycles.
Side Effects
Generally well tolerated. Possible water retention, mild joint aches, and tingling (common with GH elevation). Rare hypoglycemia.
Contraindications
Use with caution in insulin-resistant individuals. Not for use during pregnancy or with active malignancy.
Dosage Notes
Almost always stacked with Ipamorelin (1:1 ratio) for synergistic GH release. Administer on an empty stomach for optimal results.
Sourcing Notes
Widely available from research peptide suppliers. Requires refrigeration. Reconstitute with bacteriostatic water. Verify HPLC purity.
Research Papers
CJC-1295 increases GH and IGF-1 in healthy adults
Teichman et al. · Journal of Clinical Endocrinology & Metabolism · 2006
Educational use only. This profile is for informational purposes and does not constitute medical advice. Consult a qualified healthcare provider before beginning any peptide protocol.
Often Stacked With
Want a personalized protocol?
Our AI Advisor will incorporate CJC-1295 into a complete stack tailored to your goals and health context.
Start Assessment